| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Zearalanone targets estrogen receptors (ERalpha and ERbeta), acting as a non-steroidal estrogenic compound. It binds to these receptors with high affinity, mimicking the effects of natural estrogens. Activation of estrogen receptors by zearalanone leads to the regulation of estrogen-responsive genes, which can result in various physiological effects, including reproductive toxicity and endocrine disruption. The compound's estrogenic activity is well-characterized and has been studied extensively in the context of mycotoxin toxicology. Zearalanone is a valuable tool for studying estrogen receptor signaling and the effects of environmental estrogens.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Zearalanone binds to estrogen receptors with high affinity and activates estrogen-responsive gene expression. The compound's estrogenic activity has been characterized using cell-based reporter assays, where it stimulates the expression of reporter genes under the control of estrogen response elements. Zearalanone has also been shown to stimulate the proliferation of estrogen-responsive cancer cell lines, such as MCF-7 breast cancer cells. The compound's in vitro activity is well-documented and serves as a basis for its use as a research tool in endocrinology and toxicology.
|
| ln Vivo |
In vivo studies have demonstrated that Zearalanone produces estrogenic effects in animals, including reproductive toxicity, alterations in estrous cycle, and effects on fertility. The compound has been shown to cause hyperestrogenism in pigs, cattle, and other animals, leading to reproductive disorders such as vulvovaginitis, infertility, and reduced litter size. In rodents, zearalanone has been shown to affect reproductive development and function. These in vivo effects are attributed to the compound's ability to bind to estrogen receptors and activate estrogen signaling pathways. Zearalanone is studied extensively in the context of mycotoxin toxicology and food safety.
|
| Enzyme Assay |
The in vitro receptor binding assay for Zearalanone typically involves measuring the compound's affinity for estrogen receptors using radioligand binding techniques. Membrane preparations or cell lysates containing ERalpha or ERbeta are incubated with a radiolabeled estrogen (such as ^3H-estradiol) and varying concentrations of Zearalanone. Nonspecific binding is determined in the presence of excess unlabeled diethylstilbestrol or other estrogen receptor ligands. The compound's affinity (Ki value) for the receptors is calculated from competition binding experiments. These assays are standard for characterizing the estrogenic activity of compounds.
|
| Cell Assay |
Cellular assays for Zearalanone are typically conducted using estrogen-responsive cell lines, such as MCF-7 breast cancer cells. Cells are cultured in estrogen-free medium and treated with varying concentrations of Zearalanone. Cell proliferation is measured using MTT or other cell viability assays. Estrogen receptor activation is assessed using reporter gene assays, where cells are transfected with a reporter plasmid containing estrogen response elements linked to a luciferase or other reporter gene. These cell-based assays confirm the compound's estrogenic activity and provide information about its potency and efficacy.
|
| Animal Protocol |
In vivo animal studies for Zearalanone are conducted in rodents, pigs, and other animals. The compound is administered orally or by injection, and its effects on reproductive function, hormone levels, and tissue histology are assessed. In female animals, the estrous cycle is monitored, and ovarian and uterine weights are measured. In male animals, testicular weight and spermatogenesis are assessed. Hormone levels, including estradiol, progesterone, and testosterone, are measured in blood samples. These studies confirm the compound's estrogenic effects and help to characterize its toxicity profile.
|
| ADME/Pharmacokinetics |
Zearalanone has a molecular weight of approximately 320.38 and a molecular formula of C18H24O5. The compound is a white to off-white crystalline solid. It is soluble in organic solvents such as methanol, ethanol, and DMSO, but has limited solubility in water. Zearalanone is relatively stable under normal storage conditions but should be protected from light and moisture. The compound is metabolized in the liver and excreted primarily in urine and feces. Detailed pharmacokinetic parameters are available from toxicological studies on zearalenone and its metabolites.
|
| Toxicity/Toxicokinetics |
Toxicological data for Zearalanone are well-characterized due to its importance as a mycotoxin. The compound exhibits estrogenic toxicity, causing reproductive disorders in animals at relatively low doses. Chronic exposure to zearalanone can lead to reproductive toxicity, endocrine disruption, and potential carcinogenic effects. The compound is classified as a potential endocrine disruptor and is regulated in food and feed in many countries. The toxicological profile of zearalanone is similar to that of zearalenone, and both compounds are studied extensively in the context of food safety and mycotoxin toxicology.
|
| References | |
| Additional Infomation |
Zearalenone belongs to the resorcinol class of compounds, which is a macrocyclic lactone. It has been reported that pomegranates contain zearalenone, and relevant data are available for reference.
Zearalanone is a non-steroidal estrogenic mycotoxin produced by Fusarium species. It is used primarily as a research tool in the study of estrogen receptor signaling and as a reference standard for the analysis of mycotoxins in food and feed. The compound has a molecular formula of C18H24O5 and a molecular weight of approximately 320.38. Zearalanone exhibits estrogenic activity and can cause reproductive disorders in animals. It is not approved for clinical use and is available for research purposes only. The compound is regulated in food and feed due to its potential health effects. |
| Molecular Formula |
C₁₈H₂₄O₅
|
|---|---|
| Molecular Weight |
320.38
|
| Exact Mass |
320.162
|
| CAS # |
5975-78-0
|
| PubChem CID |
108003
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
576.8±50.0 °C at 760 mmHg
|
| Melting Point |
184-186ºC
|
| Flash Point |
209.2±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.526
|
| LogP |
3.45
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
23
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@H]1CCCC(=O)CCCCCC2=C(C(=CC(=C2)O)O)C(=O)O1
|
| InChi Key |
APJDQUGPCJRQRJ-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C18H24O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h10-12,20-21H,2-9H2,1H3/t12-/m0/s1
|
| Chemical Name |
(4S)-16,18-dihydroxy-4-methyl-3-oxabicyclo[12.4.0]octadeca-1(14),15,17-triene-2,8-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~312.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1213 mL | 15.6065 mL | 31.2129 mL | |
| 5 mM | 0.6243 mL | 3.1213 mL | 6.2426 mL | |
| 10 mM | 0.3121 mL | 1.5606 mL | 3.1213 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
